NewsBenzinga赛尔德克斯报告了公司在慢性自发性荨麻疹患者中评估两种剂量的巴索伏利单抗的3期EMBARQ-CSU1和EMBARQ-CSU2试验的头等结果；结果显示出迅速、深远、持久的疗效，支持巴索伏利单抗作为CSU转化疗法的潜力。 赛尔德克斯报告了公司在慢性自发性荨麻疹患者中评估两种剂量的巴索伏利单抗的3期EMBARQ-CSU1和EMBARQ-CSU2试验的头等结果；结果显示出迅速、深远、持久的疗效，支持巴索伏利单抗作为CSU转化疗法的潜力。 Benzinga 2026.09.22 11:05 (GMT+0) Open on Benzinga Other news Bitmine Immersion Technologies (BMNR) Announces ETH Holdings Reach 6.04 Million Tokens, and Total Crypto and Total Cash & Marketable Securities Holdings of $15.1 Billion Piper Sandler Maintains Overweight on Halliburton, Lowers Price Target to $42 Eos Energy Enterprises Now Expects FY26 Revenue In Lower Half Of Its $300M To $350M Range CME Group Earnings Are Imminent; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call Dan Ives Says Meta, SpaceX and Tesla Face Big Questions This Week — His 3 'Big Focus Points' Ahead of Tech Earnings Mizuho Maintains Outperform on Equifax, Lowers Price Target to $185
Bitmine Immersion Technologies (BMNR) Announces ETH Holdings Reach 6.04 Million Tokens, and Total Crypto and Total Cash & Marketable Securities Holdings of $15.1 Billion
CME Group Earnings Are Imminent; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call
Dan Ives Says Meta, SpaceX and Tesla Face Big Questions This Week — His 3 'Big Focus Points' Ahead of Tech Earnings
